Abbott Laboratories (ABT) Q4 2016 earnings summary

Executive summary

• 2016 sales were $20.853B, up 2.2% reported and 4.8% excluding FX; operating earnings rose to $3.185B from $2.867B.

• Net earnings were $1.400B vs. $4.423B; diluted EPS was $0.94 vs. $2.92, reflecting significant non-recurring and investment-related items.

• The January 2017 St. Jude Medical acquisition expanded cardiovascular and neuromodulation reach; integration and product launches are key 2017 priorities.

Financial highlights

• Net sales were $20.853B vs. $20.405B; operating earnings were $3.185B vs. $2.867B; earnings from continuing operations were $1.063B vs. $2.606B.

• Q4 sales were $5.333B vs. $5.188B; continuing-operations earnings were $875M vs. $695M; net earnings were $798M vs. $767M.

• Operating cash flow was $3.203B vs. $2.966B; capital expenditures were $1.121B; cash and equivalents ended the year at $18.620B.

• Continuing-operations taxes included a $225M net tax benefit; other expense included a $947M Mylan share valuation charge and a $480M Venezuela FX loss.

Outlook and guidance

• 2017 priorities include integrating St. Jude Medical, coordinating vascular businesses, delivering cardiovascular and neuromodulation launches, and pursuing nutrition margin improvements.

• Diagnostics planned to launch the full Alinity suite across Europe and additional geographies, including the U.S., over the next two years.

• R&D spending was expected to approximate 7.5% of sales in 2017; pension contributions were expected to be ~$364M.

• Operating cash flow was expected to continue exceeding capital expenditures and cash dividends; investment-grade ratings were expected to be maintained.